Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02105116 · ClinicalTrials.gov registry record · NA
AML Therapy With Irradiated Allogeneic Cells
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02105116 is a NA study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 6 participants.
The verdict
NCT02105116, a NA study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from a HLA haploidentical relative. Only patients who obtain a CR after the standard induction chemotherapy are eligible for the experimental therapy (irradiated haploidentical cells).
Interventions
- OTHER laboratory biomarker analysis
- DRUG G-CSF
- DRUG fludarabine phosphate
- DRUG cytarabine
- BIOLOGICAL donor lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02105116
The ClinicalTrials.gov registry entry for NCT02105116 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT02105116 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02105116 about?
NCT02105116 is a clinical study titled "AML Therapy With Irradiated Allogeneic Cells". This pilot clinical trial studies if cells donated by a close genetic relative can help maintain acute myeloid leukemia (AML) complete remission (CR). Eligible patients will receive a standard induction chemotherapy. If a complete remission results they will receive irradiated allogeneic cells from ...
What is the current status of trial NCT02105116?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2014-02. Estimated completion is 2015-12-16.
What interventions are being tested in trial NCT02105116?
The interventions under investigation include: laboratory biomarker analysis (OTHER), G-CSF (DRUG), fludarabine phosphate (DRUG), cytarabine (DRUG), donor lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT02105116?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.